EC Approves First Gene Replacement Therapy for Adults and Older Children with Spinal Muscular Atrophy

The European Commission has officially authorized the first gene replacement therapy for older children, teenagers, and adults suffering from spinal muscular atrophy (SMA). Approved on July 2, 2026, the therapy, marketed as Itvisma, marks a profound shift in neuromuscular medicine. For the first time, patients over the age of two have access to a one-time genetic intervention designed to halt the progression of a disease that progressively robs them of their ability to walk, eat, and breathe.[1][2][4]

Spinal muscular atrophy is a rare, devastating genetic disorder affecting approximately one to two in every 100,000 people globally. It is caused by a bi-allelic mutation or deletion in the survival motor neuron 1 (SMN1) gene. Without a functional SMN1 gene, the body cannot produce enough SMN protein, leading to the rapid degeneration of motor neurons in the spinal cord and brainstem.[2]

Until recently, the only gene therapy available for SMA was Zolgensma, a revolutionary intravenous treatment approved exclusively for infants under the age of two. While highly effective, Zolgensma’s delivery mechanism presented a biological ceiling. Because it is administered into the bloodstream, the viral load required to successfully cross the blood-brain barrier in older, heavier patients would be dangerously high, risking severe liver toxicity.

The newly approved Itvisma circumvents this biological roadblock through a localized delivery method. Rather than an intravenous drip, the therapy is administered via a single intrathecal injection—directly into the cerebrospinal fluid surrounding the spinal cord. This allows the genetic payload to reach the motor neurons immediately, requiring a significantly lower volume of the drug and eliminating the need to adjust the dose based on the patient's body weight.[1]

The mechanism of action relies on an adeno-associated virus (AAV9) vector, a harmless, engineered virus stripped of its own viral DNA. This vector acts as a microscopic delivery vehicle, carrying a fully functional, synthetic copy of the human SMN1 gene into the nuclei of the patient's surviving motor neurons. Once inside, the new gene begins producing the critical SMN protein, effectively addressing the root cause of the disease.[4]

The clinical evidence supporting the European Commission’s decision is anchored by the Phase 3 STEER trial, a randomized, double-blind, sham-controlled study. The trial evaluated the efficacy of intrathecal gene therapy in treatment-naïve patients aged two to eighteen. Over a 52-week period, researchers tracked patient progress using the Hammersmith Functional Motor Scale Expanded (HFMSE), a rigorous clinical tool used to measure motor function in neuromuscular diseases.[1]

The results demonstrated a statistically significant and clinically meaningful divergence between the two groups. Patients who received the gene therapy exhibited an average improvement of 2.39 points on the HFMSE scale, compared to a marginal 0.51-point change in the sham control group. In the context of SMA, where the natural trajectory is a relentless, linear decline in motor function, a multi-point gain represents a stabilization that can fundamentally alter a patient's independence.[1]

Beyond treatment-naïve patients, the regulatory approval was heavily supported by the Phase 3b STRENGTH trial, which evaluated the therapy in a real-world population. This open-label study focused on patients who had previously been treated with, and subsequently discontinued, chronic SMA therapies such as Spinraza or Evrysdi. The data confirmed that the intrathecal gene therapy provided sustained motor function stabilization even in patients who were transitioning from older treatment modalities.[1][4]

For the SMA community, the approval represents more than just a new molecular pathway; it is a paradigm shift in the daily reality of disease management. Existing therapies for older patients require either daily oral medication or lifelong, tri-annual lumbar punctures to inject maintenance drugs into the spine. The prospect of a 'one-and-done' treatment removes the immense logistical, physical, and psychological burden of chronic dosing.[3][4]

Patient advocacy groups have heralded the decision as a critical step toward equitable care. Representatives from SMA Europe emphasized that maintaining or slightly improving motor function in a teenager or adult can mean the difference between operating a motorized wheelchair independently or requiring round-the-clock assistance. The focus has now shifted from sheer survival—the primary goal in infantile SMA—to preserving long-term quality of life and autonomy.[3]

The European authorization follows the U.S. Food and Drug Administration's approval of the same therapy in late 2025, signaling a growing global consensus on the safety and efficacy of intrathecal AAV9 vectors. Regulatory bodies on both sides of the Atlantic have concluded that the localized delivery successfully mitigates the systemic toxicity risks that previously barred older patients from accessing gene replacement technology.[4]

However, the evidence pack also highlights necessary clinical precautions and transparent uncertainties. Because the therapy utilizes a viral vector, patients are required to undergo a course of corticosteroids before and after the injection to suppress the immune system and prevent a severe inflammatory response. Hepatotoxicity, or liver damage, remains a monitored risk, requiring rigorous blood tests in the months following the procedure.[2]

Another critical limitation is the presence of pre-existing immunity. Patients who have naturally contracted an AAV9 virus in the past may carry neutralizing antibodies that would attack and destroy the gene therapy before it can enter the motor neurons. Consequently, all prospective patients must undergo antibody screening, and those with high titers are currently ineligible for the treatment.[4]

The long-term durability of the therapy also remains an open question in the scientific community. While data from the earliest infantile gene therapy trials show sustained efficacy approaching a decade, it is not yet definitively known whether the synthetic SMN1 gene will continue to express the necessary protein for the entire lifespan of an adult patient. Because the immune system develops permanent antibodies against the AAV9 vector after the first dose, the therapy can never be re-administered.[4]

Despite these uncertainties, the clinical consensus views the approval as a landmark achievement. By proving that gene therapy can be safely adapted for older, heavier patients through localized delivery, researchers have not only transformed the prognosis for thousands of SMA patients but also established a viable blueprint for treating a wide array of other genetic central nervous system disorders.[4]